검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Chemotherapy and antibodies (Chemotherapy and antibodies) Shanghai Hengrui Pharmaceutical Co…·Acute Myeloid Leukemia 61 trials·t½ 7 h |
|---|---|
Overview Program | Chemotherapy and antibodies |
Overview Company | Shanghai Hengrui Pharmaceutical Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Acute Myeloid Leukemia; Acute Lymphocytic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting bone-remodeling pathway |
MoA Biomarker | biomarkers |
PK/PD Half-life | 7 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy.. Hematopoietic stem cell transplantation (HSCT) of genetically engineered cells is a promising treatment modality for monogenic diseases. However, hematopoietic stem cell (HSC)-directed lentiviral vector (LV) gene therapies remain limited by genotoxicities associate… |
Toxicology CRS | 71% |
Clinical PFS | 5.1 |
Clinical OS | 7.2 |
Clinical Result source | ClinicalTrials.gov NCT05718466 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Chemotherapy and antibodies (Chemotherapy and antibodies) Shanghai Hengrui Pharmaceutical Co…·Acute Myeloid Leukemia 61 trials·t½ 7 h |
|---|---|
Overview Program | Chemotherapy and antibodies |
Overview Company | Shanghai Hengrui Pharmaceutical Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Acute Myeloid Leukemia; Acute Lymphocytic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting bone-remodeling pathway |
MoA Biomarker | biomarkers |
PK/PD Half-life | 7 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Antimetabolites synergize with non-genotoxic antibody drug conjugate conditioning in hematopoietic stem cell lentiviral gene therapy.. Hematopoietic stem cell transplantation (HSCT) of genetically engineered cells is a promising treatment modality for monogenic diseases. However, hematopoietic stem cell (HSC)-directed lentiviral vector (LV) gene therapies remain limited by genotoxicities associate… |
Toxicology CRS | 71% |
Clinical PFS | 5.1 |
Clinical OS | 7.2 |
Clinical Result source | ClinicalTrials.gov NCT05718466 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교